Mayne Pharma and Mithra announce TGA approval of Nextstellis® oral contraceptive

/in /by

29 November 2021, 08:45, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets). Mayne Pharma anticipates the commercial […]

Read more
/in /by

Liege, Belgium, November 29, 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the holding of its Investor Day today at its R&D and production center, the Mithra CDMO in Flémalle, Belgium. As of 9:00 am CET, all presentations can be simultaneously followed by webcast on the […]

Read more

Information on the Total Number of Voting Rights Following the Completion of the LDA Capital Increase

/in , /by

Liege, Belgium, 10 November 2021 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below […]

Read more

Mithra organizes its Investor Day on November 29, 2021

/in /by

Liege, Belgium, 10 November 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host an Investor Day on Monday, November 29, 2021 at 9:00 am CET. The event will be broadcasted live via webcast, the link will be available soon on Mithra’s website.

Read more

Mithra Announces Estelle® Launch in Belgium

/in /by

Liege, Belgium, 21 October 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is very pleased to announce that its novel combined oral contraceptive Estelle® is now available in Belgium. The product is marketed in Belgium by Richter under the brand name Drovelis® and by Ceres Pharma under the […]

Read more

The Board of Directors confirms Leon Van Rompay as Mithra’s CEO

/in /by

Liege, Belgium, 15 October 2021 – 17:45 CEST – The Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, has confirmed the appointment of Mr. Leon Van Rompay as Chief Executive Officer of the company, a position he held ad interim since February 04, 2021.

Read more

Mithra Provides FDA Update on Myring®

/in /by

Liege, Belgium, 6 October 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its US commercial partner Mayne Pharma (ASX:MYX) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to the abbreviated new drug application (ANDA) for Myring®, […]

Read more

Mithra Announces the Appointment of its Representative to Mayne Pharma’s Board of Directors

/in /by

Liege, Belgium, 4 October 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is pleased to announce that it has joined the Board of Mayne Pharma Group Limited, in accordance with the license and supply agreement to commercialize Nextstellis® (E4/DRSP) oral contraceptive in the United States. As Mayne Pharma’s […]

Read more

Mithra Announces Topline Results for COVID-19 Phase II Study

/in /by

Liege, Belgium, 24 September 2021 – 7:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces topline results of the Coronesta Phase II study, which aimed to assess the safety and efficacy of estetrol (E4) for the treatment of patients who were hospitalized with moderate COVID-19. E4 is a native […]

Read more

Mithra Announces 2021 Half Year Results

/in /by

Liege, Belgium, 24 September 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the six-month period ending on 30 June 2021, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.

Read more